Story excerpt provided by Crain’s Cleveland Business.
Federal regulators have been kind to Juventas Therapeutics.
The Cleveland company’s experimental heart failure drug has been granted Fast Track status from the U.S. Food and Drug Administration.
That status — which is designed to speed up the FDA’s review process — should help Juventas get through its upcoming Phase IIb clinical trial. The FDA also gave Juventas permission to proceed with that trial.
Click here to read the complete article.
Originally published June 16, 2015.